Hepatitis B e antigen and the risk of hepatocellular carcinoma.

By Hwai I. Yang, Sheng-Nan Lu, Y. Liaw, S. You, Chien‐An Sun, Li‐Yu Wang, Chuhsing Kate Hsiao, Pei‐Jer Chen, Ding‐Shinn Chen, Chien-Jen Chen. New England Journal of Medicine, 2002

1,276 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/e0056e5ffd2090bba220eb2f53c743d960d1179b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. M. Kudo

In Hepatology

1. M. Kudo
2. A. Cheng

Citations in the corpus

• Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. (2008, background): “5-fold among cigarette smokers compared to non-smokers [96], whereas in the population-based cohort study of more than 3500 HBsAg carriers from Taiwan smoking did not affect the HCC risk [HR (95% CI): 1.”
• Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. (2009, background): “These include patient factors including male gender, increasing age [3]; virological factors including hepatitis B e antigen positivity, high serum HBV DNA levels, genotype C compared to B, precore mutations and core promoter mutations [4–11]; and disease factors including alanine aminotransferase (”
• iArc monogrAphs on the evAluAtion oF cArcinogenic risks to humAns (2012, background): “In these studies, the cohorts consisted of general populations of both genders (Chang et al., 1994; Nomura et al., 1996; Lu et al., 1998; Evans et al., 2002; Yang et al., 2002; Wang et al., 2003a; Gwack et al., 2007), Army recruits (Evans et al.”
• Epidemiology and Prevention of Hepatitis B Virus Infection (2005, background): “A prospective study in Taiwan [62] showed that relative risk of HCC among men who were positive for both HBsAg and HBeAg (RR=60.”
• Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection (2013, neutral): “Baseline ALT level (IU/L) 42 (22-88) 70 (42-163) 33 (20-68) <0.”
• Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update (2015, background): “It can be subdivided into HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB).”
• Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. (2006, background): “The increased hepatocellular carcinoma risk in individuals seropositive for HBeAg remained significant regardless of serum level of alanine aminotransferase (ALT) and status of liver cirrhosis.(8,9)”
• Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update (2012, methodology): “The community-based REVEAL-HBV study demonstrated that seropositivity for HBeAg and/or HBV DNA [10 copies/mL ([2,000 IU/mL) in adult HBV carriers at study entry are significant risk factors for cirrhosis and HCC development over time in a dose-dependent manner [24–26].”